Multiple myeloma (MM) is a disease with variable presentation, disease trajectory, prognosis, and options for treatment. Integrating the plethora of scientific discovery relative to plasma cell disorders, molecular and cytogenetic attributes and their implications for prognosis and treatment, identification of key components of the bone marrow micro - environment, and the development of novel therapies targeting many of these attributes requires a thorough review of multiple sources of information. Multiple Myeloma: A Textbook for Nurses, edited by Joseph D.
Chemotherapy-induced nausea and vomiting (CINV) remains common despite the availability of new antiemetic agents and the development of clinical guidelines by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Multinational Association of Supportive Care in Oncology.1-3 It is estimated that 70% to 80% of patients who receive chemotherapy experience CINV; approximately 10% to 44% experience anticipatory nausea and vomiting.
To sign up for our newsletter or print publications, please enter your contact information below.